Breo(688793)

Search documents
倍轻松(688793) - 国投证券股份有限公司关于深圳市倍轻松科技股份有限公司2024年度募集资金存放与使用情况的专项核查意见
2025-04-28 17:06
国投证券股份有限公司 关于深圳市倍轻松科技股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 国投证券股份有限公司(以下简称"国投证券"、"保荐机构")作为深圳 市倍轻松科技股份有限公司(以下简称"倍轻松"、"公司")首次公开发行股 票并在科创板上市持续督导阶段的保荐机构,根据《证券发行上市保荐业务管理 办法》《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》 《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》《上海证 券交易所科创板股票上市规则》《深圳市倍轻松科技股份有限公司募集资金管理 制度》(以下简称"《募集资金管理制度》")等有关规定,对倍轻松2024年度 募集资金存放与使用情况进行了审慎核查,核查的具体情况如下: 一、募集资金基本情况 (一)实际募集资金金额、资金到位时间 根据中国证券监督管理委员会出具的《关于同意深圳市倍轻松科技股份有限 公司首次公开发行股票注册的批复》(证监许可〔2021〕1965号),公司首次向 社会公众公开发行人民币普通股(A股)1,541万股,每股面值1元,每股发行价 格为人民币27.40元,募集资金总额为人民币422,234,00 ...
倍轻松:2024年报净利润0.1亿 同比增长119.61%
Tong Hua Shun Cai Bao· 2025-04-28 16:46
Financial Performance - The company reported a basic earnings per share of 0.1200 yuan for 2024, a significant increase of 120% compared to -0.6000 yuan in 2023 [1] - The net profit for 2024 was 0.1 billion yuan, showing a remarkable recovery from a loss of -0.51 billion yuan in 2023, representing a 119.61% increase [1] - Operating revenue decreased by 14.9% to 10.85 billion yuan in 2024 from 12.75 billion yuan in 2023 [1] - The return on equity improved to 2.72% in 2024 from -11.75% in 2023, indicating a positive turnaround [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 58.365 million shares, accounting for 67.92% of the circulating shares, with a decrease of 1.8675 million shares compared to the previous period [1] - Major shareholder Ma Xuejun holds 34.7879 million shares, representing 40.48% of the total share capital, with no change in holdings [2] - New entrants among the top shareholders include Baoying Core Advantage Mixed A and Li Hu, while Shenzhen Hongjun Capital Management and Guangdong Wuwen Private Securities Fund Management have exited the top ten [2] Dividend Distribution - The company has announced no dividend distribution or capital increase for the current period [3]
倍轻松(688793) - 2025 Q1 - 季度财报
2025-04-28 16:45
Financial Performance - The company's operating revenue for Q1 2025 was ¥197,014,270.73, a decrease of 32.83% compared to ¥293,298,831.57 in the same period last year[3]. - The net profit attributable to shareholders was -¥1,832,539.23, representing a decline of 111.74% from ¥15,610,139.93 year-over-year[3]. - The net cash flow from operating activities was -¥61,743,909.04, a significant drop of 249.34% compared to ¥41,344,340.75 in the previous year[3]. - The basic earnings per share were -¥0.02, a decrease of 111.11% from ¥0.18 in the same period last year[3]. - The diluted earnings per share also stood at -¥0.02, reflecting the same decline of 111.11%[4]. - The weighted average return on equity was -0.50%, a decrease of 4.28 percentage points from 3.78% in the previous year[4]. - The net profit for Q1 2025 was a loss of ¥1,799,351.33, compared to a profit of ¥15,610,102.87 in Q1 2024[20]. - The company reported total comprehensive income of 2,615,933.08 RMB for the period, a decrease from 7,117,100.71 RMB in the previous period[29]. Assets and Liabilities - Total assets at the end of the reporting period were ¥620,184,156.97, down 23.56% from ¥811,387,085.16 at the end of the previous year[4]. - As of March 31, 2025, the company's total assets amounted to RMB 620,184,156.97, a decrease from RMB 811,387,085.16 as of December 31, 2024, representing a decline of approximately 23.5%[14]. - The company's current assets totaled RMB 472,153,536.87, down from RMB 659,873,627.43, indicating a decrease of about 28.5%[15]. - Total liabilities decreased to ¥247,948,593.04 in Q1 2025 from ¥441,348,946.74 in Q1 2024[17]. - The company's total liabilities decreased to 364,950,797.95 RMB from 464,926,360.60 RMB in the previous period[27]. Cash Flow - The net cash flow from investment activities was 29,391,441.42 RMB, a significant improvement compared to a net outflow of 33,700,550.94 RMB in the previous period[23]. - Total cash inflow from financing activities reached 126,560,000.00 RMB, up from 80,000,000.00 RMB in the prior period[23]. - The company reported a net decrease in cash and cash equivalents of 81,650,291.02 RMB, compared to a smaller decrease of 3,813,744.59 RMB in the previous year[23]. - The net cash flow from operating activities for Q1 2025 was -90,564,306.60 RMB, a significant decline compared to 25,231,971.03 RMB in Q1 2024[32]. - The company reported a total cash outflow from operating activities of 271,977,251.86 RMB in Q1 2025, compared to 297,217,352.04 RMB in Q1 2024, indicating a decrease of about 8.5%[32]. Research and Development - Research and development expenses totaled ¥13,253,647.44, accounting for 6.73% of operating revenue, an increase of 1.62 percentage points from 5.11% in the previous year[4]. - Research and development expenses for Q1 2025 were ¥13,253,647.44, down from ¥14,897,402.33 in Q1 2024[19]. - Research and development expenses for Q1 2025 were 11,657,808.97 RMB, slightly lower than 12,313,360.45 RMB in Q1 2024[28]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,381[9]. - The top shareholder, Ningbo Heting Investment Co., Ltd., holds 6,340,000 shares, representing 7.38% of total shares[12]. - The company reported a total of 1,531,321 shares held in the repurchase account, which are not included in the top 10 shareholders list[10]. - The company has not reported any changes in the top 10 shareholders due to securities lending activities[13].
倍轻松(688793) - 2024 Q4 - 年度财报
2025-04-28 16:45
Financial Performance - The company reported a negative cumulative undistributed profit as of the end of 2024, leading to no profit distribution, cash dividends, or capital reserve transfers for the year[3]. - The company has not achieved profitability since its listing, indicating ongoing financial challenges[3]. - The company's operating revenue for 2024 was approximately ¥1.085 billion, a decrease of 14.88% compared to ¥1.275 billion in 2023[21]. - The net profit attributable to shareholders for 2024 was ¥10.25 million, a significant improvement from a loss of ¥50.87 million in 2023[21]. - The basic earnings per share for 2024 was ¥0.12, compared to a loss of ¥0.60 per share in 2023[22]. - The company's total assets increased by 8.39% to approximately ¥811.39 billion in 2024, up from ¥748.59 billion in 2023[21]. - The company's net assets attributable to shareholders decreased by 8.55% to approximately ¥370.04 million at the end of 2024, down from ¥404.65 million at the end of 2023[21]. - The company achieved revenue of 1,085.12 million yuan and net profit of 10.19 million yuan, marking a turnaround from loss to profit year-on-year[30]. - The company reported a net profit of ¥15.61 million in Q1 2024, with a decline in profits in subsequent quarters[28]. - The company reported a significant increase in other income by 260.13% to ¥30,763,845.11, mainly from government subsidies[144]. Risk Management - The company has detailed various risks and countermeasures in its report, highlighting the importance of risk management in its operations[3]. - The company has faced non-operating fund occupation by controlling shareholders and other related parties[5]. - The company has not reported any violations of decision-making procedures regarding external guarantees[5]. - The company is at risk of losing core competitiveness if it fails to keep up with technological advancements in the industry[114]. - The company faces intensified competition in the smart portable massager industry, necessitating continuous innovation and market adaptation[115]. - The gross margin has decreased due to various factors, and there is a risk of further decline if competitive pressures increase[117]. - The company has a high sales expense ratio due to its direct sales model, which may continue to impact overall profitability[118]. Corporate Governance - The company has not disclosed any special arrangements for corporate governance, indicating a standard governance structure[4]. - The governance structure includes various committees to enhance decision-making efficiency[171]. - The company has established a governance structure compliant with relevant laws and regulations, ensuring effective operation of the general meeting, board of directors, and supervisory board[171]. - The company has not reported any significant changes in the independence of its operations or any major competition issues with its controlling shareholders[176]. - There were no changes in the shareholding of directors and senior management during the reporting period[176]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 797.24 million RMB[186]. - The total remuneration for core technical personnel at the end of the reporting period was 165.34 million RMB[186]. - The company held a total of 8 board meetings during the year, with all resolutions passed without any objections[189]. - The audit committee convened 5 meetings during the reporting period to discuss the annual report and internal audit plans[191]. Research and Development - Research and development expenses accounted for 5.38% of operating revenue in 2024, an increase of 0.79 percentage points from 4.59% in 2023[23]. - Total R&D investment amounted to ¥58,345,886.58, a slight decrease of 0.27% compared to the previous year, with R&D investment as a percentage of operating income increasing to 5.38% from 4.59%[92]. - The company has 105 R&D personnel, accounting for 11.03% of the total workforce, down from 11.55% in the previous year[95]. - The company applied for 29 invention patents and obtained 24 invention patent authorizations during the reporting period, bringing the total number of various intellectual property rights to 1,919, including 863 authorized patents[89]. - The company has established partnerships with research institutions to accelerate technological innovation and product development, ensuring a competitive edge in the market[83]. - The company’s new product development includes a focus on AI health detection and user interaction improvements[94]. - The company has developed four core systems: Breo Super Bionic, Breo Hyper Motion, Breo TCMDT, and Breo Pro-Health-M, enhancing its technological capabilities in the portable massage device sector[79][80]. Product Development and Innovation - The company launched a laser hair care massage comb registered with the FDA, utilizing low-level laser therapy (LLLT) to stimulate hair follicles and improve scalp vitality, paving the way for entry into the high-end health market in Europe and the US[30]. - A subscription-based sleep improvement plan was introduced, combining hardware data with cloud health models to create a complete service chain from monitoring to intervention[31]. - The product matrix has been optimized, with over ten new massage products launched, including the N6mini neck and shoulder massager, which won the JD 2024 Annual Lightning New Product Project Gold Award[36]. - The company’s innovative technologies include AI-driven personalized massage experiences and IoT connectivity for remote control and customization through mobile apps[66][68]. - The company is focusing on integrating modern technology with traditional Chinese medicine to innovate portable health products, establishing itself as a leader in the smart portable massager industry[48]. - The company has developed a differentiated strategy combining traditional Chinese medicine with modern technology, enhancing its competitive edge in the market[104]. - The company is committed to a dual-driven technology strategy of "Traditional Chinese Medicine × Technology," aiming to redefine health care through intelligent health companions[161]. Market Expansion and Sales Strategy - The company has established a multi-channel sales strategy, leveraging both traditional and emerging e-commerce platforms to drive sales growth[40]. - The company is transitioning its offline stores to a new model that combines technology products with quick-effect massage services, enhancing consumer experience and brand loyalty[39]. - The company has established a diversified business matrix covering "smart hardware + rapid massage services + health AI + pan-health ecosystem" to enhance its strategic positioning[158]. - The company plans to accelerate its global market expansion, focusing on Southeast Asia and the Middle East, with a goal to establish a comprehensive sales network by 2025[166]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence, with a focus on companies in the health tech sector[182]. - The company is enhancing its digital marketing efforts, aiming for a 40% increase in online sales channels[182]. - The company has successfully expanded its market presence, selling its products in regions such as Europe, the United States, Japan, and Southeast Asia, enhancing its global footprint[106]. Customer Engagement and Satisfaction - User data showed a total of 5 million active users, representing a 15% increase compared to the previous quarter[178]. - Customer satisfaction ratings improved to 90%, indicating a strong brand loyalty among users[178]. - The company is enhancing its user service system, focusing on personalized recommendations and improving customer satisfaction feedback mechanisms[169]. Future Outlook - The company provided an optimistic outlook, projecting a revenue growth of 20% for the next fiscal year[178]. - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[182]. - New product launches are expected to contribute an additional $50 million in revenue over the next year[178]. - The company plans to enhance its product line, which currently includes smart portable massagers for various body parts, and plans to introduce more age-friendly products to cater to the growing elderly population[163]. - The company aims to reduce operational costs by 15% through efficiency improvements in the supply chain[178]. - The company is investing in R&D for innovative products, with a budget allocation of $10 million for the upcoming year[181]. Employee Management and Training - The total number of employees in the parent company is 244, while the total number of employees in major subsidiaries is 708, resulting in a combined total of 952 employees[198]. - The company follows a competitive and fair compensation policy, aiming to attract and retain core talent through a comprehensive salary and benefits system[199]. - The training plan for 2024 focuses on enhancing employees' professional skills, management capabilities, and innovative abilities, aligning with the company's strategic goals[200]. - New employee training includes courses on corporate culture, business processes, and practical internships to facilitate smooth onboarding[200].
倍轻松(688793) - 2024年度独立董事述职报告-李勇
2025-04-28 16:42
深圳市倍轻松科技股份有限公司 深圳市倍轻松科技股份有限公司 2024 年度独立董事述职报告 (独立董事:李勇) 本人李勇,作为深圳市倍轻松科技股份有限公司(以下简称"公司")的独 立董事,2024 年度,本人严格按照《中华人民共和国公司法》《中华人民共和 国证券法》《上海证券交易所科创板股票上市规则》《上市公司独立董事管理办 法》等法律、法规以及《深圳市倍轻松科技股份有限公司章程》等要求,谨慎、 忠实、勤勉地履职尽责,努力发挥独立董事的作用,审慎认真地行使公司和股东 所赋予的权利,及时关注公司经营情况,积极参加股东大会、董事会及专门委员 会会议,对公司董事会审议的相关重大事项发表公正、客观的独立意见,维护公 司和中小股东的合法权益,为公司的长远发展出谋划策,对董事会的科学决策、 规范运作以及公司发展起到了积极作用。现将本人在 2024 年度履行独立董事职 责的情况报告如下: 一、独立董事的基本情况 (一)个人工作履历、专业背景以及兼职情况 李勇,1957 年 10 月生,中国国籍,无境外永久居留权,本科学历。1981 年 4 月至 1995 年 11 月,任重庆钢铁集团公司党校讲师、经济师;1995 年 11 ...
倍轻松(688793) - 2024年度独立董事述职报告-梁文昭
2025-04-28 16:42
本人梁文昭,作为深圳市倍轻松科技股份有限公司(以下简称"公司")的 独立董事,2024 年度,本人严格按照《中华人民共和国公司法》《中华人民共 和国证券法》《上海证券交易所科创板股票上市规则》《上市公司独立董事管理 办法》等法律、法规以及《深圳市倍轻松科技股份有限公司章程》等要求,谨慎、 忠实、勤勉地履职尽责,努力发挥独立董事的作用,审慎认真地行使公司和股东 所赋予的权利,及时关注公司经营情况,积极参加股东大会、董事会及专门委员 会会议,对公司董事会审议的相关重大事项发表公正、客观的独立意见,维护公 司和中小股东的合法权益,为公司的长远发展出谋划策,对董事会的科学决策、 规范运作以及公司发展起到了积极作用。现将本人在 2024 年度履行独立董事职 责的情况报告如下: 深圳市倍轻松科技股份有限公司 深圳市倍轻松科技股份有限公司 2024 年度独立董事述职报告 (独立董事:梁文昭) 一、独立董事的基本情况 (一)个人工作履历、专业背景以及兼职情况 梁文昭,1970 年 11 月出生,中国国籍,无境外永久居留权,研究生学历。 1993 年至 2002 年,任安达信会计师事务所高级经理。2002 年 11 月至 20 ...
倍轻松(688793) - 2024年度独立董事述职报告-陈晓峰
2025-04-28 16:42
深圳市倍轻松科技股份有限公司 深圳市倍轻松科技股份有限公司 2024 年度独立董事述职报告 (独立董事:陈晓峰) 本人陈晓峰,作为深圳市倍轻松科技股份有限公司(以下简称"公司")的 独立董事,2024 年度,本人严格按照《中华人民共和国公司法》《中华人民共 和国证券法》《上海证券交易所科创板股票上市规则》《上市公司独立董事管理 办法》等法律、法规以及《深圳市倍轻松科技股份有限公司章程》等要求,谨慎、 忠实、勤勉地履职尽责,努力发挥独立董事的作用,审慎认真地行使公司和股东 所赋予的权利,及时关注公司经营情况,积极参加股东大会、董事会及专门委员 会会议,对公司董事会审议的相关重大事项发表公正、客观的独立意见,维护公 司和中小股东的合法权益,为公司的长远发展出谋划策,对董事会的科学决策、 规范运作以及公司发展起到了积极作用。现将本人在 2024 年度履行独立董事职 责的情况报告如下: 一、独立董事的基本情况 (一)个人工作履历、专业背景以及兼职情况 陈晓峰,1965 年 10 月出生,无境外永久居留权,本科学历。1988 年 7 月至 1994 年 6 月,赣南医学院第一附属医院泌尿外科担任住院医师、主治医师;19 ...
倍轻松:证监会发布关于2024年度内控审计意见相关事项的监管工作函
news flash· 2025-04-28 14:27
倍轻松公告,证监会发布关于2024年度内控审计意见相关事项的监管工作函,涉及对象为上市公司,董 事,监事,高级管理人员,控股股东及实际控制人,中介机构及其相关人员。 ...
倍轻松(688793) - 关于变更持续督导保荐代表人的公告
2025-04-21 10:16
证券代码:688793 证券简称:倍轻松 公告编号:2025-019 深圳市倍轻松科技股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 1 / 3 备查文件: 1. 《国投证券股份有限公司关于变更深圳市倍轻松科技股份有限公司保荐代表 人的申请报告》; 2. 张双先生出具的《保荐代表人声明与承诺书》; 深圳市倍轻松科技股份有限公司(以下简称"公司")于 2021 年 7 月 15 日完 成首次公开发行股票并在上海证券交易所科创板上市,保荐机构国投证券股份有限 公司(以下简称"国投证券")委派保荐代表人任国栋先生、翟平平先生担任公司 首次公开发行股票并在科创板上市持续督导保荐代表人,负责具体持续督导工作, 督导期限至 2024 年 12 月 31 日止。因上述期限届满后公司募集资金尚未使用完毕, 国投证券仍需就公司尚未使用完毕的募集资金履行持续督导义务。 2021 年 10 月,因任国栋先生离职,不再担任公司的保荐代表人,由顿忠清先 生接替担任公司的保荐代表人并履行持续督导职责。此 ...
倍轻松(688793) - 关于以集中竞价交易方式首次回购公司股份的公告
2025-04-17 10:04
证券代码:688793 证券简称:倍轻松 公告编号:2025-018 深圳市倍轻松科技股份有限公司 关于以集中竞价交易方式首次回购公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 深圳市倍轻松科技股份有限公司董事会 中竞价方式回购股份的回购报告书》(公告编号:2025-017) 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定,现将公司首次回购股份的具体情况公告如下:2025 年 4 月 17 日,公司通过上海证券交易所交易系统以集中竞价交易方式首次回购股 份 5,200 股,占截至 2025 年 4 月 17 日公司总股本 85,945,419 股的比例为 0.01%, 回购成交的最高价为 27.26 元/股,最低价为 26.93 元/股,支付的资金总额为人 民币 140,231.55 元(不含印花税、交易佣金等交易费用)。本次回购股份符合法 律法规的规定及公司的回购股份方案。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证 ...